Trial | NCT01487278  Report issue

Title

Comparing Misoprostol and Oxytocin in UnijectTM for Postpartum Hemorrhage (PPH) Prevention in Mali
Preventing Postpartum Hemorrhage: Examining Two Strategies for PPH Prevention in Communities: Misoprostol and Oxytocin in UnijectTM in Mali

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Withdrawn

  • Intervention/Treatment

    misoprostol ...

  • Study Participants

    0
This is a large, community-based, cluster-randomized trial to compare routine prophylactic use of 600 mcg oral misoprostol and 10 IU oxytocin delivered by UnijectTM intramuscularly during the third stage of labor.
This study will assess the programmatic implications (including feasibility, acceptability, costs, risks and benefits) at the community level of the introduction of misoprostol and/or oxytocin in UnijectTM for the prevention of PPH and will help to identify the appropriate niche for both drugs.
Study Started
Dec 05
2011
Last Update
Jan 09
2014
Estimate

Drug misprostol

600 mcg misoprostol oral

  • Other names: Cytotec

Device UnijectTM

10 IU oxytocin delivered intramuscularly with UnijectTM

Misoprostol Experimental

600 mcg oral misoprostol administered during the third stage of labor

UnijectTM Experimental

10 IU oxytocin delivered IM with UnijectTM during he third stage of labor

Criteria 

Inclusion Criteria:

women delivering at home with a trained study provider who are able to provide informed consent

Exclusion Criteria:

women with known contraindications to prostaglandins
No Results Posted